Recent progress of antiviral therapy for coronavirus disease 2019

[1]  Yvette N. Lamb.  Remdesivir: First Approval , 2020, Drugs.

[2]  A. Gurung.  In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors , 2020, Gene Reports.

[3]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[4]  M. Müller,et al.  Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.

[5]  X. de Lamballerie,et al.  Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates , 2020, Nature.

[6]  Lee-Jen Wei,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[7]  R. Baric,et al.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.

[8]  S. Anzick,et al.  Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.

[9]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[10]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[11]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[12]  Jianping Huang,et al.  Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study , 2020, Microbes and Infection.

[13]  E. Clementi,et al.  Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? , 2020, The Journal of antimicrobial chemotherapy.

[14]  P. Ravaud,et al.  Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data , 2020, BMJ.

[15]  J. Qu,et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.

[16]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[17]  C. Wen,et al.  [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study]. , 2020, Zhonghua nei ke za zhi.

[18]  I. Olaoye,et al.  Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus , 2020, Journal of biomolecular structure & dynamics.

[19]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[20]  Z. Memish,et al.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review , 2020, Travel Medicine and Infectious Disease.

[21]  E. Castañón,et al.  A Trial of Lopinavir-Ritonavir in Covid-19. , 2020, The New England journal of medicine.

[22]  H. Shan,et al.  Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 , 2020, medRxiv.

[23]  Y. Xiong,et al.  Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection , 2020, BMJ Case Reports.

[24]  P. Zimetbaum,et al.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[25]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[26]  Mina T. Kelleni.  Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management , 2020, Pharmacological Research.

[27]  Dr Irin Hossain, MPH,et al.  The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) In Bangladesh: A Descriptive Study , 2020, Journal of Medical Science And clinical Research.

[28]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[29]  S. S. Alinaghi,et al.  A Patient with COVID-19 Disease in a Referral Hospital in Iran: A Typical Case. , 2020, Infectious disorders drug targets.

[30]  L. Epstein,et al.  Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection , 2020, Circulation. Arrhythmia and electrophysiology.

[31]  J. Huang,et al.  Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study , 2020, Clinical Microbiology and Infection.

[32]  S. Jois,et al.  The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, bioRxiv.

[33]  Catherine M. Brown,et al.  Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020, Nature Medicine.

[34]  Alex John London,et al.  Against pandemic research exceptionalism , 2020, Science.

[35]  T. C. I. team.  Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020 .

[36]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[37]  W. Alhazzani,et al.  COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine , 2020, Journal of Clinical Epidemiology.

[38]  M. Müller,et al.  Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[39]  M. Lill,et al.  Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds , 2020, International journal of molecular sciences.

[40]  Zhen Zhu,et al.  Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 , 2020, Journal of Infection.

[41]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[42]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[43]  Duanqing Pei,et al.  Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.

[44]  Lei Liu,et al.  The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients , 2020, Inflammation Research.

[45]  Q. Tong,et al.  COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression , 2020, The Journal of antimicrobial chemotherapy.

[46]  Q. Ding,et al.  The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China , 2020, Journal of medical virology.

[47]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[48]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[49]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[50]  Rui-guang Zhang,et al.  Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[52]  Z. Hong,et al.  Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.

[53]  Hongzhou Lu,et al.  [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[54]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[55]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[56]  L. Hong,et al.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. , 2020, European review for medical and pharmacological sciences.

[57]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[58]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[59]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[60]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[61]  Novel Coronavirus Pneumonia Emergency Response Epidemiol Team.  [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[62]  A. Wilder-Smith,et al.  Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak , 2020, Journal of travel medicine.

[63]  T. Velavan,et al.  The COVID‐19 epidemic , 2020, Tropical medicine & international health : TM & IH.

[64]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[65]  Wei Zhang,et al.  Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. , 2020, Bioscience trends.

[66]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[67]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[68]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[69]  Catharine I Paules,et al.  Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.

[70]  Joy Y. Feng,et al.  Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir , 2019, Viruses.

[71]  Clemens Vonrhein,et al.  Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA , 2017, Proceedings of the National Academy of Sciences.

[72]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[73]  I. Wilson,et al.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol , 2016, Proceedings of the National Academy of Sciences.

[74]  Sumudu P Leelananda,et al.  Computational methods in drug discovery , 2016, Beilstein journal of organic chemistry.

[75]  Makoto Takeda,et al.  Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay , 2016, Antimicrobial Agents and Chemotherapy.

[76]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[77]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[78]  Yanchen Zhou,et al.  Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.

[79]  J. Rossignol.  Nitazoxanide: A first-in-class broad-spectrum antiviral agent , 2014, Antiviral Research.

[80]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[81]  S. Polyak,et al.  Arbidol as a broad-spectrum antiviral: An update , 2014, Antiviral Research.

[82]  D. Smee,et al.  Favipiravir (T-705), a novel viral RNA polymerase inhibitor. , 2013, Antiviral research.

[83]  K. To,et al.  Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.

[84]  Chengyu Jiang,et al.  Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model , 2012, Cell Research.

[85]  C. Yurdaydın,et al.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C , 2011, Nature Reviews Gastroenterology &Hepatology.

[86]  I. Ben-Zvi,et al.  Hydroxychloroquine: From Malaria to Autoimmunity , 2011, Clinical Reviews in Allergy & Immunology.

[87]  Andrew Hill,et al.  How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials , 2009, AIDS.

[88]  N. Buckley,et al.  Survival after Massive Hydroxychloroquine Overdose , 2009, Anaesthesia and intensive care.

[89]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[90]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[91]  D. Raoult,et al.  Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century , 2007, International Journal of Antimicrobial Agents.

[92]  Paul J. Hertzog,et al.  Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.

[93]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[94]  Roberto Cauda,et al.  New insights into the antiviral effects of chloroquine , 2006, The Lancet Infectious Diseases.

[95]  F. Romanelli,et al.  Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. , 2004, Current pharmaceutical design.

[96]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[97]  Jindrich Cinatl,et al.  HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.

[98]  A. Cassone,et al.  Effects of chloroquine on viral infections: an old drug against today's diseases , 2003, The Lancet Infectious Diseases.

[99]  Elizabeth J Phillips,et al.  Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  C. Cameron,et al.  Ribavirin's antiviral mechanism of action: lethal mutagenesis? , 2002, Journal of Molecular Medicine.

[101]  A. Carmichael,et al.  Fatal toxic epidermal necrolysis associated with hydroxychloroquine , 2001, Clinical and experimental dermatology.

[102]  P. Tebas,et al.  Nelfinavir mesylate , 2000, Expert opinion on pharmacotherapy.

[103]  Vinita B Pai,et al.  Nelfinavir Mesylate: A Protease Inhibitor , 1999, The Annals of pharmacotherapy.

[104]  O. Weiland,et al.  The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. , 1998, The Journal of general virology.

[105]  A. Hsu,et al.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.

[106]  B. Portmann,et al.  Fulminant hepatic failure secondary to hydroxychloroquine. , 1994, Gut.

[107]  T. Muramatsu,et al.  Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate. , 1988, Journal of the American Academy of Dermatology.

[108]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[109]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[110]  J. Beijnen,et al.  Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs , 2004, Clinical pharmacokinetics.

[111]  Asmar.  Therapeutic Efficacy , 2020, Definitions.